Skip to main content
logo
X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.240
+0.040 (1.25%)
At close: Oct 23, 2026, 4:00 PM EDT
3.250
+0.010 (0.31%)
After-hours: Oct 23, 2026, 7:30 PM EDT

X4 Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-90.14-79.2-37.45-101.17-93.87-88.7
Depreciation & Amortization
1.671.280.80.420.510.5
Other Amortization
0.90.870.860.930.920.76
Loss (Gain) From Sale of Assets
---105---
Asset Writedown & Restructuring Costs
-----9.76
Stock-Based Compensation
8.534.38.28.695.26.18
Other Operating Activities
1.56-10.28-0.98-5.724.42.1
Change in Accounts Receivable
-0.90.5-1.07---
Change in Inventory
-2.33-1.66-2.82---
Change in Accounts Payable
-3.78-2.98-0.291.233.431.17
Change in Unearned Revenue
-0.151.09----
Change in Other Net Operating Assets
0.910.486.85-0.892.31-2.66
Operating Cash Flow
-83.74-85.62-130.9-96.51-77.1-70.91
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
---0.33-0.06-0.1-0.62
Sale of Property, Plant & Equipment
--105---
Sale (Purchase) of Intangibles
-5-3-7---
Investment in Securities
11.4311.15-30.68-14.82--
Investing Cash Flow
6.438.1566.99-14.88-0.1-0.62

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
--2022.5--
Long-Term Debt Repaid
----2.06-0.8-
Net Debt Issued (Repaid)
--2020.44-0.8-
Issuance of Common Stock
233.07238.630.2968.71122.8476.25
Repurchase of Common Stock
-----0.01-2
Other Financing Activities
----0.63-4.8-
Financing Cash Flow
233.07238.6320.2988.52117.2374.25

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-0.020.21-0.160.1-0.11-0.32
Net Cash Flow
155.75161.38-43.77-22.7839.922.41

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-83.74-85.62-131.23-96.57-77.21-71.52
Free Cash Flow Growth
------
Free Cash Flow Margin
-528.40%-243.84%-5132.07%---
Free Cash Flow Per Share
-0.82-2.02-19.58-16.29-36.46-83.33
Levered Free Cash Flow
-53.31-57.36-83.72-59.79-44.23-43.05
Unlevered Free Cash Flow
-48.74-52.68-79.09-57.1-42.65-41.53

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
8.058.057.774.63.012.91
Cash Income Tax Paid
0.340.34----
Change in Working Capital
-6.25-2.582.680.345.74-1.5
SEC Filings: 10-K · 10-Q